Skip to main content

MCL Status Granted For Taxotere Hair Loss Lawsuits

MCL Status Granted For Taxotere Hair Loss Lawsuits

MCL Status Granted For Taxotere Hair Loss Lawsuits

Introduction

The New Jersey Supreme Court announced a multicounty (MCL) status for hair-loss lawsuits against Taxotere manufacturers on Tuesday, confirming the centralization of the cases in the Garden State and assigned the group to Superior Court Judge James Hyland.

The Justices published a notice on August 15, granting multicounty litigation status to about 353 such cases against Sanofi U.S. Services Inc., Sanofi-Aventis U.S. LLC, Sandoz Inc. and Actavis LLC, all of which allege the makers failed to adequately warn consumers about the potential health risks of Taxotere use. Chief Justice Stuart Rabner approved the application on August 17.

A significant number of Taxotere cases were already before Judge Hyland before the designation as a mass tort. About 9,100 Taxotere lawsuits are centralized as a multidistrict litigation (MDL No.2740; In Re: Taxotere (Docetaxel) Products Liability Litigation) for pretrial proceedings Eastern District of Louisiana overlooked by Judge Kurt D. Engelhardt.  All of the lawsuits claim the chemotherapy drug is prone to cause permanent hair loss, the bellwether trial for the same is expected to begin in May 2019.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.